Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools ACC

ACC

Programs, trials, and reported response and survival for adenoid cystic carcinoma.

Data as of 11.07.2026

ACC pipeline

What is next, and who is running it?

Programs by company or class, across phase, filing, approval, and a stop.

A black mark is a readout. A yellow mark is another company date. A circle is an approval or an FDA action date the source names. A hollow mark is a registry primary completion date.

Phase 1 on
ClassNone selected

Phase 1 included.

Clear filters

23 of 23 programs on this matrix

Phase 1Phase 2Phase 3FiledApprovedDiscontinued
AstraZeneca1 program
Ayala Pharmaceuticals1 program
Cellestia Biotech1 program
CB-103

Registry, Jun 2027

oral (not re-verified)

pan-NOTCH transcription inhibitor · Cellestia Biotech

Dana-Farber Cancer Institute1 program
Ivonescimab

Registry, Jul 2027

Dosing n/r

PD-1 x VEGF bispecific · Dana-Farber Cancer Institute

Eisai (investigator studies)1 program
Lenvatinib (off Label)

Registry, Dec 2026

once daily, oral

VEGFR multi-kinase TKI · Eisai (investigator studies)

Elevar Therapeutics1 program
Rivoceranib

Trials stopped

once daily, oral

Registry records are terminated or withdrawn.

VEGFR2 TKI · Elevar Therapeutics

Exelixis1 program
Eye and ENT Hospital of Fudan University1 program
HitGen1 program
HG146

Registry, Dec 31, 2028

Dosing n/r

HDAC inhibitor · HitGen

Memorial Sloan Kettering1 program
Enfortumab Vedotin

Registry, Mar 2027

Dosing n/r

Nectin-4-directed ADC · Memorial Sloan Kettering

Memorial Sloan Kettering (investigator)1 program
National Cancer Centre Singapore1 program
National Cancer Institute1 program
SX-682 + Docetaxel

Registry, Oct 2036

Dosing n/r

CXCR1/2 inhibitor · National Cancer Institute

Novelty Nobility1 program
NN3201

Registry, Aug 30, 2027

Dosing n/r

KIT-directed ADC · Novelty Nobility

Pfizer1 program
Radboud UMC; Johns Hopkins (investigators)1 program
Remix Therapeutics (merging with Passage Bio)1 program
REM-422

ENA 2026 late-breaking oral 5LBA (updated Phase 1), Nov 19, 2026

once daily, oral, once daily

MYB mRNA degrader · Remix Therapeutics (merging with Passage Bio)

Rgenta Therapeutics1 program
RGT-61159

Phase 3 start (company plan), Q1 2027

once daily, oral, once daily

MYB splicing modulator · Rgenta Therapeutics

Servier (registry sponsor Day One Biopharmaceuticals)1 program
Shanghai Ninth People's Hospital1 program
Apatinib

Phase 2

Dosing n/r

VEGFR2 TKI · Shanghai Ninth People's Hospital

Trisha Wise-Draper (investigator)1 program
Amivantamab

Phase 2

intravenous

EGFR x MET bispecific antibody · Trisha Wise-Draper (investigator)

University of Michigan1 program
VM Oncology1 program
VMD-928

Registry, Dec 2027

Dosing n/r

TrkA inhibitor · VM Oncology